LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Chiusa

SettoreSettore sanitario

141.65 -0.71

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

141.19

Massimo

142.41

Metriche Chiave
By Trading Economics
Entrata	-60M -365M
Dipendenti	883
EBITDA	-59M -348M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+24.17% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	11B 31B
Apertura precedente	142.36
Chiusura precedente	141.65

Notizie sul Sentiment di mercato

By Acuity

32%

68%

108 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

40.67 / 41.96 Supporto e resistenza

REVOLUTION Medicines Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 gen 2026, 11:10 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 gen 2026, 20:13 UTC

I principali Market Mover

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 ott 2025, 18:13 UTC

I principali Market Mover

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 gen 2026, 09:55 UTC

Azioni calde

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 gen 2026, 19:58 UTC

Acquisizioni, Fusioni, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 gen 2026, 14:54 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 gen 2026, 10:54 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 gen 2026, 14:49 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 gen 2026, 12:38 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 gen 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 gen 2026, 20:29 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

Revolution Has Market Value of Around $16B -- WSJ

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Near Deal for Revolution Medicines -- WSJ

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

Deal May Come Soon, Sources Say -- WSJ

7 gen 2026, 19:48 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Confronto tra pari

Modifica del prezzo

REVOLUTION Medicines Inc Previsione

Obiettivo di Prezzo

By TipRanks

24.17% in crescita

Previsioni per 12 mesi

Media 176.95 USD 24.17%

Alto 263 USD

Basso 140 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

40.67 / 41.96Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

108 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.